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Need for randomized clinical trials testing targeted therapies in malignant pleural mesothelioma
Dear Sir/s,
In regard to the article “Targeting BAP1: a new paradigm for mesothelioma” by Laurel M. Schunselaar et al., which appeared in Lung Cancer
(2017); 109: 145–146, discussing BAP1 pathway as a promising therapeutic target for treating mesotheliomas, we would like to discuss the need for
randomized clinical trials evaluating the targeted therapies in this disease.
Malignant Pleural Mesothelioma (MPM) is a rare and aggressive tumour aﬀecting the internal lining of the pleura. It is characterized by a poor
prognosis and patients normally do not live longer than 12 months [1]. The main cause of this disease is known to be asbestos, although there are
some studies pointing at the involvement of Simian virus 40 in its pathogenesis [2–4]. Other factors that may be involved in the pathogenesis include
environmental exposure to erionite, ﬂuoro-edenite and ionizing radiation as well as exposure to ceramic ﬁbres [1,5]. The current standard treatment
is the combination of cisplatin with pemetrexed [6,7]. However the average survival for this tumour still remains around 1 year. Hence there is an
urgent need for a better understanding of the underlying biology of the disease to identify new actionable targets and improve patients’ outcomes. In
fact, no targeted therapies have been approved so far for the treatment of the disease. Using data collected from the literature on the very few
randomized MPM clinical trials available, we performed a meta-analysis with the aim of investigating the eﬃcacy of targeted therapies in MPM.
The studies were identiﬁed according to the following inclusion criteria: 1) participants with advanced MPM; 2) novel targeted agents as the
experimental drug; 3) the presence of a control arm for comparison 4) a primary outcome of OS expressed as the hazard ratio (HR) and secondary
outcomes of progression-free survival (PFS) expressed as HR. The following exclusion criteria were used: 1) insuﬃcient data were available to
estimate the outcomes; 2) animal studies; 3) size of each arm less than 10 participants; 4) non-randomized studies and 5) studies without molecular
agents. The summary estimates were generated using a ﬁxed-eﬀect model (Mantel–Haenszel method) [8] or a random-eﬀect model (DerSimo-
nian–Laird-method) [9] depending on the absence or presence of heterogeneity (I2).
The search yielded 253 potentially relevant articles; 172 studies were excluded, as they were duplicates. After viewing the titles and abstracts of
the 81 remaining studies, the full texts of 19 studies were retrieved. Sixteen studies were excluded because they were not Randomized-to controls
(RTCs). Finally, 3 studies [10–12] were included in the analysis (Table 1).
A total of 1330 MPM cases were randomly assigned to receive either designated controls or one of three experimental treatments including bev-
acizumab, thalidomide or vorinostat. In the ﬁrst study, the combination of pemetrexed and cisplatin was tested with or without bevacizumab (MAPS) in
chemotherapy naive patients [10]; in the second study patients who completed ﬁrst-line chemotherapy received either thalidomide together with active
supportive care or active supportive care alone (NVALT-5) [11]; in the third study patients were either treated with vorinostat or placebo (VANTAGE-014)
[12]. With regard to overall survival (OS), the pooled analysis revealed that targeted therapies improved the OS in comparison to the control arm
(HR= 0.95, 95% CI: 0.76–1.19; P = 0.68, Fig. 1A), even though this result lacks statistical signiﬁcance. The analysis was performed using a random-
eﬀects model due to the absence of heterogeneity (I2 = 0%). When looking at progression free survival (PFS), the pooled analysis showed a statistically
signiﬁcant improvement related to the use of targeted therapies (HR= 0.75, 95% CI: 0.60–0.94; P = 0.01 Fig. 1B). The random-eﬀects model was used
for the analysis of the PFSs due to the presence of high heterogeneity (I2 = 72%) among the considered trials.
Data from the literature clearly indicated the lack of randomized clinical trials testing targeted treatments for mesothelioma. In fact only three RTCs
studies met our search criteria. The anti-angiogenic (anti-VEGF) monoclonal antibody bevacizumab combined with standard cisplatin and pemetrexed
treatment signiﬁcantly improved PFS and OS [10]. Thalidomide, another anti-angiogenic and immunomodulating compound, induces apoptosis of new
vasculatures as well as stimulates an immune response against cancer cells. When given to MPM patients as second line therapy, however, it failed to
induce a measurable anti-tumour response [11]. Conversely, histone deacetylase inhibitor vorinostat on its own was able to improve PFS, while not OS,
suggesting potential eﬃcacy in combination regimens [12]. From our analysis, only 2 of the 3 targeted therapies, bevacizumab and vorinostat, showed
statistical improvement of PFS of MPM patients. It is worth considering that targeted drugs could be more eﬃcient when used in combination with other
therapies, as the elicited cytostatic eﬀect may not be “enough” to generate a measurable anti-tumour response in the single-agent setting. As our report
suggests, there is a need for more RTCs studies testing targeted therapies, both as single therapy and in combination with other targeted and/or systemic
drugs. The main drawback in mesothelioma clinical trials is the small number of patients enrolled, because of the intrinsic nature of the disease. In fact,
MPM patients are relatively low in number because of the biology of the tumour and the fact that the disease is generally diagnosed in its late stages.
However larger cohorts of patients enrolled in randomized trials would increase the reliability and scientiﬁc signiﬁcance of the ﬁndings.
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Table 1
Characteristics of the analysed trials.
Study Phase Primary endpoint Number of
Patients Exp Arm
Number of
Patients Control
Arm
Line Exp arm Control arm Jaded
Score
MAPS [10] III Overall survival 223 225 I pemetrexed plus cisplatin
plus bevacizumab.
pemetrexed plus
cisplatin
4
NVALT-5 [11] III Time to
progression
111 110 Maintenance After
ﬁrst line
Thalidomide Supportive care 5
VANTAGE-014
[12]
III Overall survival/
safety
329 332 II vorinostat Placebo 5
Fig. 1. (A) Forest plots of hazard ratios (HRs) for overall survival (OS) comparing new targeted therapies to the control arm. (B) Forest plots of hazard ratios (HRs) for progression free
survival (PFS) comparing new targeted therapies to control arm.
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